15 April 2019 - Deborah Wilkes
Pierre Fabre has appointed Sanofi's Jean-Luc Lowinski as chief executive officer of the Pierre Fabre Pharmaceuticals division.
He is responsible for Pierre Fabre's oncology, prescription drugs and consumer healthcare businesses. He also sits on the French company's Executive Committee.
Lowinski, 54, joined Sanofi in 2012 as vice president Asia. In 2017, he moved to Sanofi Genzyme as vice president of Emerging Markets.
Before joining Sanofi, Lowinski spent 20 years with Bayer where he worked in the company's Healthcare and Consumer Care businesses. During that time, he worked in China, India, Japan, Singapore, South Korea and Thailand.
Pierre Fabre Pharmaceuticals employs around 6,000 people and generated sales of EUR880 million (USD987 million) in 2018. Its consumer healthcare brands include Drill, Elgydium, Eludril, Naturactive, Nicopatch, Pedi-Relax and Structum.
The division accounted for 38% of Pierre Fabre's 2018 sales of EUR2.33 billion. The remainder was generated by Pierre Fabre Dermocosmetics.
Around 63% of sales came from the French company's international business.
Pierre Fabre is 86% owned by the Pierre Fabre Foundation.
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE